Evidence map›Paper›PMID 41907187›Full record

ArticleImmuno2026

Conditional Stat2 Knockout Mice as a Platform for Modeling Human Diseases.

Tess Cremers, Nataliya Miz, Alexandra Afanassiev, Ling Yang, Kevin P Kotredes, Ana M Gamero

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immuno, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tess CremersDepartment of General Surgery, Cooper University Hospital, Camden, NJ 08103, USA.
Nataliya MizDepartment of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
Alexandra AfanassievDepartment of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
Ling YangDepartment of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
Kevin P KotredesThe Jackson Laboratory, Bar Harbor, ME 04609, USA.
Ana M GameroDepartment of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.

Funding

STAT2 Signaling in the Pathogenesis of PsoriasisR21AR078350 · NIAMS · TEMPLE UNIV OF THE COMMONWEALTH · PI GAMERO, ANA M · 2021 to 2022
$382k
Investigation of STAT2 Signaling in the tumor microenvironmentR03CA273613 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI GAMERO, ANA M · 2023 to 2024
$229k
The Role of STAT2 in Flat Non-Polypoid Colorectal NeoplasiaR03CA215929 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI GAMERO, ANA M · 2017 to 2018
$156k
Evaluation of STAT2 in a Model of Sporadic Colorectal CancerR03CA162545 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI GAMERO, ANA M · 2011 to 2012
$153k
NCI NIH HHS R03 CA162545NCI NIH HHS R03 CA215929NCI NIH HHS R03 CA273613NIAMS NIH HHS R21 AR078350
6 · The paper itself

Abstract

Signal transducer and activator of transcription 2 (STAT2) is a key component of the type I interferon (IFN-I/III) signaling pathway, which is pivotal in host defense against cancer and viral infections and in shaping immune responses. Building on our previously reported conditional

Indexed as

antiviralconditional knockoutCre deletionSTAT2tissue-specific deletiontumortype I interferon

Identifiers

PMID41907187
PMCPMC13026504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.